

Legend

- 1 Pharmacologic–Therapeutic Classification.
- 2 Pharmacologic–Therapeutic sub-classification.
- 3 Nonproprietary or generic ingredient name of the drug.
- 4 Drug strength and dosage form.
- 5 The Drug Identification Number (DIN), assigned by the Therapeutic Products Directorate (TPD), Health Protection Branch, Health Canada, or Natural Product Number (NPN) assigned by the Natural and Non-prescription Health Products Directorate (NNHPD). For other types of Drug Products or Devices, a Product Identification Number (PIN) will be assigned.
- 6 A box containing an X to the left of the DIN/NPN/PIN indicates that the product is not interchangeable with other products or interchangeability has not been assessed within the category.
- 7 All active ingredients of combination Drug Products are listed.
- 8 Strengths of active ingredients are listed in the same order as the ingredients. This example indicates that the topical cream contains 0.5 mg/g hydrocortisone acetate and 30 mg/g salicylic acid.
- 9 Brand name of the Drug Product or Device.
- 10 Three letter identification code assigned to each manufacturer. The codes are listed in Appendix 2 at the end of the List.
- 11 For Drug Products which are marked as non-interchangeable, the price is indicated in regular type (not bold type). These prices are supplied by the manufacturer and are expressed in decimal dollars.
- 12 For those Drug Products and Devices which are single source, the price is indicated in regular type (not bold type). These prices are supplied by the manufacturer and are expressed in decimal dollars.
- 13 Interchangeable grouping where the Least Cost Alternative (LCA) Price Policy has not been applied. This example indicates these two Drug Products are deemed interchangeable. These prices are supplied by the manufacturer and are expressed in decimal dollars.
- 14 The LCA Price for the selected interchangeable category appears in bold type. The LCA price is the maximum price which will be paid. The prices listed are expressed as decimal dollars. An authorized health care provider may request special authorization if a particular brand is essential in the care of a patient where the LCA Price would otherwise apply. For further information refer to the Special Authorization Guidelines section of the ADBL or List.
- 15 Drug Products or Devices designated as restricted benefits and limited restricted benefits are identified by a comment after the generic name. The comment indicates “RESTRICTED BENEFIT” or “LIMITED RESTRICTED BENEFIT” along with an explanation of the limits and/or restrictions. In this example, coverage of Emend is restricted to the drug being prescribed by the Directors of Alberta Health Services – Cancer Care “Cancer Centres” (or their designates). For more information about Drug Products or Devices designated as restricted benefits, refer to the restricted benefits section of the List.
- 16 A MAC Grouping means a grouping of Drug Products or Devices that have been listed on the ADBL or the List as being subject to a MAC Price; a MAC Grouping may include a grouping of IC Drugs, in which case the grouping shall be treated as an Established IC Grouping. Groupings subject to MAC Price will have the maximum amount established by the Minister which will be paid by the Government of Alberta.

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.